Masimo (MASI) Stock
Medical device maker focused on patient monitoring systems. Here's the price, business snapshot, and what's worth knowing about Masimo in July 2026.
Masimo Corporation (ticker: MASI) develops non‑invasive monitoring technologies and patient‑monitoring systems used in hospitals, ambulatory settings and by consumers. Its product range includes advanced pulse oximetry sensors, monitoring platforms and software that aggregate physiological data for clinicians, alongside newer efforts in wearable and home monitoring. Revenue comes from device sales, sensors and recurring consumables, and software services; the company emphasises R&D and intellectual property as competitive assets. With a market capitalisation around $8.06 billion, Masimo sits among mid‑cap medical‑technology names and faces competition from larger equipment makers and emerging digital-health firms. Key considerations for investors include sensitivity to hospital procurement cycles, regulatory approvals, and potential litigation or patent disputes — all of which can affect results. Masimo’s business can offer exposure to healthcare’s structural demand for monitoring, but performance may be volatile; this summary is educational only, not personalised investment advice, and prospective investors should consider risk tolerance and seek professional guidance.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Masimo's stock, expecting its value to rise to $183.75.
Financial Health
Masimo is showing strong revenue and cash generation, indicating good overall financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
Abbott
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
AGILENT TECHNOLOGIES INC
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment provides contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represent a range of offerings designed to serve customer needs across end-markets and applications.
ALIGN TECHNOLOGY INC
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
Baskets Featuring MASI
Liver Disease Therapies | Next-Gen FDA Approvals
The FDA's recent accelerated approval of Gilead's Hepcludex has established the first legal treatment for a deadly liver infection known as hepatitis D. This milestone opens the door for investors to explore opportunities in companies developing innovative liver disease therapies, specialized diagnostics, and advanced patient monitoring systems.
Published: 26 May 2026
Explore BasketWearable Health Stocks: Growth Potential vs Competition
Apple's recent FDA clearance for its Apple Watch hypertension feature marks a major step in wearable medical technology. This development opens up investment opportunities in the broader ecosystem of connected health devices and remote patient monitoring services.
Published: 12 September 2025
Explore BasketWearable Tech IP Wars: What Investors Should Know
Masimo's lawsuit against U.S. Customs, following a reversal of an import ban on Apple Watches, highlights the fierce competition over intellectual property in wearable health. This theme focuses on the medical technology companies and competitors poised to benefit from the ongoing patent battles in the lucrative health-monitoring device market.
Published: 21 August 2025
Explore BasketWhy You’ll Want to Watch This Stock
Non‑invasive monitoring
Masimo’s core sensors and monitors address steady clinical demand for safer, continuous vital‑sign tracking — though sales can fluctuate with hospital procurement cycles.
Hospital to home
Growing interest in remote and home monitoring could expand Masimo’s addressable market, while reimbursement and regulatory pathways remain key variables.
Technology differentiator
R&D and intellectual property underpin Masimo’s product positioning, but patent disputes and competition are ongoing considerations for investors.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
